News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Dec. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2018 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne -- -- Submission represents ongoing advancement of the company’s proprietary PMO RNA-based platform -- CAMBRIDGE, Mass. , Dec.
View HTML
Toggle Summary Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
- Gray Recognized for Scientific and Financial Acumen as Board Leader - CAMBRIDGE, Mass. , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it appointed Mary Ann Gray , Ph.D., to its Board of
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2018 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 3,817,000 shares of its common stock at a price to the
View HTML
Toggle Summary Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
CAMBRIDGE, Mass. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten
View HTML
Toggle Summary Sarepta Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference
CAMBRIDGE, Mass. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 10:55 a.m.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2018 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments
-- Third quarter 2018 EXONDYS 51® (eteplirsen) total net revenues of $78.5 million -- CAMBRIDGE, Mass. , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.